To determine the impact (morbidity/mortality) of biliary stent-related events (SRE) (cholangitis or stent obstruction) in chemotherapy-treated pancreaticobiliary patients.
Retrospective Study
Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy to curative resection [1, 2] . In the context of advanced pancreatobiliary malignancies, chemotherapy is con sidered the standard of care treatment and corner stone of patients management; while the role of radiotherapy is not clearly stablished (even for locally advanced disease), at least in the firstline setting. Chemotherapy is given with palliative intent, its aim being to increase survival and reduce cancer related symptoms thereby improving quality of life. Systemic treatment for patients with advanced biliary tract cancer includes gemcitabine alone or given in combination with cisplatin [3] . In patients with advanced pancreatic adenocarcinoma, chemotherapy may consist of monotherapy (gemcitabine) or combination therapy [gemcitabinenabpaclitaxel doublet or FOLFIRINOX (5-fluorouracil, oxaliplatin and irinotecan)] [4, 5] . However, even with the newer chemotherapy combinations, the prognosis remains poor, with a median overall survival of less than 12 mo [5] . For patients presenting with biliary obstruction, reestablishment of biliary drainage prior to starting palliative chemotherapy is mandatory [via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC)] [6] . Two main types of biliary stents are usually employed: (1) plastic stents which have a small diameter and are used for potentiallyresectable tumours which are then removed when the curative surgery is performed; and (2) metallic stents that are usually chosen for patients with unresectable cancers because of their larger diameter [79] and therefore, longer patency [10] . Unfortunately, despite successful first biliary stenting, some patients will develop a stentrelated event (SRE) such as recurrence of biliary obstruction (with development of new obstructive jaundice) or infection (cholangitis) [11, 12] . The median patency time of metallic biliary stents is estimated to be around 3.5 to 4.0 mo, although it varies depending on the diameter and type of the stent inserted (stent patency drops to 1.6 mo with plastic biliary stents) [10, 13, 14] .
The development of a SRE has been postulated to be detrimental in many ways for the patient popu lation with pancreatobiliary cancer receiving palliative chemotherapy, leading to shorter survival (due to SRErelated lifethreatening complications) and negative impact on patients' quality of life (due to repeat hospitalisation). Moreover, chemotherapy dose intensity may be compromised as a result of admissionrelated treatment delays or discontinuations (for example, in patients with permanent deterioration of their performance status after hospitalisation). The aim of this study was to analyse the incidence (measured as SRE rate and timetoSRE) and impact of SREs in patients with advanced biliary tract and pancreatic malignancies receiving palliative chemotherapy and, in doing so, to provide reference data in order to design an adequatelypowered clinical trial to investigate the role of prophylaxis for the Lamarca A et al . Biliary stent-related events in patients receiving chemotherapy developed a SRE during follow-up [cholangitis (39%), stent obstruction (29%), both (32%)]. There were no significant differences in baseline characteristics between the SRE group and no-SRE groups. Recorded SRE-consequences were: none (37%), chemotherapy delay (24%), discontinuation (17%) and death (22%). The median time-to-SRE was 4.4 mo (95%CI: 3.6-5.5). Patients with severe comorbidities (P < 0.001) and patients with ≥ 2 baseline stents/biliary procedures [HR = 2.3 (95%CI: 1.2-4.44), P = 0.010] had a shorter time-to-SRE on multivariable analysis. Stage was an independent prognostic factor for overall survival (P = 0.029) in the multivariable analysis adjusted for primary tumour site, performance status and development of Core tip: Most patients diagnosed with advanced malignancies of the pancreas or bile ducts present with biliary obstruction; this requires biliary stenting before starting treatment with palliative chemotherapy. The impact of developing stent-related events (SRE) such as cholangitis or stent obstruction (and the potential role of prophylactic treatment in order to reduce the risk of developing SREs) has not been explored in this patient population. Our results have identified that SREs are common and adversely impact on patient's morbidity (and possibly mortality) and support the need for prospective studies investigating the role of prophylaxis in this population.
INTRODUCTION
Both pancreatic and biliary tract malignancies are known to have a poor prognosis, mainly due to late presentation of patients who experience nonspecific symptoms for some time. Because of this delay, the majority of patients (around 80%) are diagnosed with advancedstage cancer, which is not amenable prevention or delay of SREs in patients with biliary stents who are due to commence chemotherapy.
MATERIALS AND METHODS
Patients were identified retrospectively from local electronic casenote records at a single institution (The Christie NHS Foundation Trust, Manchester, United Kingdom). All consecutive patients diagnosed with hepatopancreatobiliary (HPB) malignancies referred between January 2013 and January 2015 were scree ned. The local audit committee approved this study (CE15/1400).
Eligible patients were those meeting the following inclusion criteria: advanced (unresectable or meta static) biliary tract malignancy [gallbladder, bile duct (cholangiocarcinoma) or ampullary] or pancreatic cancer (adenocarcinoma); had an in-situ biliary stent for biliary obstruction at the time of starting palliative chemotherapy; and went on to receive standard firstline palliative chemotherapy. Patients with hepato cellular carcinoma were excluded.
Demographic data [including fitness at baseline assessed by Eastern Cooperative Oncology Group Performance Status score (ECOGPS)], characteristics of the primary tumour (tumour site and stage (AJCC 7 th Edition [15] ) and details of the treatment administered were collected from the local records. Radiological response to treatment was assessed 3monthly as per Response Evaluation Criteria In Solid Tumours (RECIST v.1.1) [16] . Comorbidities in addition to the index cancer were classified according to the Adult Comorbidity Evaluation (ACE)27 index which is systematically used in our institution [17] . Characteristics of the biliary stent fitted at baseline and details of any SRE (if any) were collected. Patients who developed at least one SRE during the followup were included in the SRE group, while those who did not were included in the noSRE group.
The primary objective of this study was to assess the SRE rate and the timetoSRE in a population of patients with a diagnosis of biliary or pancreatic cancer receiving palliative chemotherapy. Secondary objectives included analysis of the impact of the development of a SRE on the patient's planned chemo therapy schedule, progressionfree survival (PFS) and overall survival (OS).
A stentrelated event (SRE) was defined as any one or more of the following: (1) any episode of jaundice which was considered significant enough for new stenting or medical treatment and was confirmed by radiological imaging to be associated with biliary dilatation; (2) any episode of infection which was clinically in keeping with cholangitis (bile duct infection) requiring antibiotic therapy; (3) bacteraemia with isolation in blood cultures of bacteria suspected to have originated in the biliary tract; and (4) any episode of cholecystitis or gallbladder perforation.
The following were not considered SREs: (1) jaundice related to high tumour burden liver disease with no significant change in biliary dilatation com pared with previous imaging; (2) episodes of neutro penic or non-neutropenic fever with no identified biliary focus; and (3) patients with nonclinically significant biliary occlusion or biliary dilatation (i.e., radiological evidence only with no jaundice, increasing bilirubin, increasing liver function tests (LFTs), fever or evidence of infection) who required no action (no new stenting or no new antibiotic therapy). Time on follow-up was defined as the time from first biliary stent insertion to date of last followup available. TimetoSRE was defined as the period between the date of the first biliary stenting and the date of the first evidence (clinical or radiological) of SRE. The median timetoSRE was calculated in patients developing a SRE during followup. The risk of developing a SRE at different timepoints was estimated for all patients, using the KaplanMeier method. For the analysis of timetoSRE, death was considered a competing event; thus, FineGray regression was employed for identification of factors related to longer/shorter time-toSRE. For multivariable analysis of factors impacting timetoSRE, those variables which showed statistically significant pvalue in the univariate analysis (p < 0.05) were included.
In order to provide data regarding the impact of chemotherapy in PFS and OS, PFS and OS were defined as the time from starting chemotherapy to the time of progression (radiological or clinical) and the date of death/last followup, respectively. Median PFS and OS were estimated by the KaplanMeier method. The logrank test and univariate/multivariable Cox regression models were used to identify poten tial prognostic factors for both PFS and OS. For assessment of factors with an impact on OS, variables considered of interest [such as site of primary tumour, stage, ECOGPS and development of SRE (SRE group vs noSRE group)] and those variables which showed statistically significant p in the univariate analysis (p < 0.05) were included in multivariable analysis.
Statistical ttest, χ 2 test and the MannWhitney test (in case of nonnormal distribution as per Shapiro
Wilk test) were applied as appropriate. Twosided significance test with a p of < 0.05 was considered significant. Stata version 12.0 software was employed for the statistical analysis.
RESULTS
A total of 693 patients diagnosed with HPB malig nancies were screened; 96 met the criteria for inclusion ( Figure 1 ). The median time of followup was 9.6 mo (range 2.2 to 26.4). By the end of the followup period, 45% and 69% of the patients had progressed and died, respectively. There were no significant differences (p = 0.1308) in median follow up between the SRE group [10.5 mo (range: 2.126.4)] and the noSRE group [8.5 mo (range 3.218.9)].
Stent-related events rate and its consequences
During followup, 41 (43%) patients developed a SRE; the type of SRE was as follows: cholangitis (16 patients; 39%), stent obstruction (12; 29%) and combination of both (13; 32%). Moreover, in 14 out of the 41 patients with a first SRE (34%), further SREs were documented. Development of at least one SRE during the followup led to the following consequences: a delay in chemotherapy (10 patients; 24%), inter ruption of chemotherapy (7; 17%) and death (9; 22%). In 15 of the patients (37%), there was no significant SRErelated repercussion. No relationship was found between type of stent and type of SRE (p = 0.815; full data not show); nor between the type of SRE and its consequence (p = 0.166; full data not shown). See Table 2 .
Time to stent-related event
The median timetoSRE was 4.4 mo (95%CI: 3.65.5) when calculated for the SRE group only. Table 3 summarises the estimated risk of SRE for all patients (SRE group and noSRE group) at different timepoints during the follow up, showing a cumulative risk of developing SRE during the time on followup. Figure  2 represents each of the patients included in this study, showing the time to SRE in the context of other clinically significant events.
Patients with severe comorbidities (vs patients with no comorbidities) (p < 0.001) and patients with ≥ 2 stent/biliary procedure before starting chemotherapy (vs 1) had shorter timetoSRE on multivariable analysis (HR = 2.3, 95%CI: 1.24.44, p = 0.010). See Table 4 .
Progression-free survival
Only nine patients (9%) were still receiving first line chemotherapy at the time of the analysis: eight in the noSRE group and one in the SRE group. The most frequent reason for stopping chemotherapy was toxicity (46%), followed by completion of planned treatment (27%), progressive disease (17%) or death (1%). Estimated median PFS was 6.7 mo (95%CI: 4.47.8), with similar results in both SRE group and noSRE group [6.7 (95%CI: 4.38.7) and 6.8 (95%CI: 3.97.8), respectively] [HR = 0.9 (95%CI: 0.61.5), p = 0.7666]. There were no statistically significant differences with respect to the reason for chemotherapy discontinuation between the SRE group and the noSRE group (p = 0.058; full data not shown).
Overall survival
The estimated median OS was 8.6 mo (95%CI: 6.89.8). Even though there seemed to be a trend for longer survival in the SRE group [median OS 9.8 mo (95%CI: 7.411.6)] than in the noSRE group [median OS 7.6 mo (95%CI: 5.79.6)] differences were not statistically significant (Logrank test p = The rate of patients who died and progressed was also similar between both groups [rate of death: 71% (SRE group) vs 67% (noSRE group); p = 0.825] [rate of progression: 54% (SRE group) vs 38% (noSRE group); p = 0.151].
Patient demographics
The median age at the time of commencing palliative chemotherapy was 66.6 years (range 2683.8) with a similar proportion of males (56%) and females (44%). The primary tumour site was as follows: 78% pancreas, 18% bile duct (cholangiocarcinoma), 3% ampulla and 1% gallbladder cancer. Most patients (60%) had locally advanced disease. All patients were fit for chemotherapy and started firstline systemic treatment as per clinician discretion. The median time between first stenting and start of chemotherapy was 1.8 mo (range: 0.112.6). The most frequently used chemotherapy schedules were single agent gemcitabine (39%) followed by gemcitabine and capecitabine combination (26%). The median time of chemotherapy duration was 3.2 mo (range 0.17.6); there were no differences in baseline characteristics between the SRE group and the noSRE group (see detail in Table 1 ). None of the patients included were on longterm antibiotics or ursodeoxycholic acid.
Biliary stenting characteristics at baseline
Most of patients had one (73%) or two (22%) biliary stents fitted at the time of starting systemic chemotherapy; only 3 patients and 1 patient had three and four stents in-situ, respectively. In 85 patients (89%), stents were metallic. A higher proportion of patients in the SRE group when compared to the no SRE group had ≥ 2 biliary stents or biliary procedures [41% (SRE group) vs 15% (noSRE group); p = 0.004]. See Table 2 . , p = 0.001] (Figure 3 ). Stage was an independent prognostic factor for OS [HR = 1.8 (95%CI: 1.062.9), p = 0.029)] in multivariable analysis adjusted for primary tumour, ECOGPS and development of SRE (SRE group vs no-SRE group) ( Table 5 ).
DISCUSSION
In patients with advanced/inoperable cancers of the pancreas or biliary tract receiving chemotherapy and with an indwelling biliary stent at the start of treatment, we observed a high rate of SREs; moreover twothirds of patients had some kind of consequence from the SRE (chemotherapy delay, discontinuation or early death). In addition, onethird of patients with a first SRE developed further events, highlighting the importance of close followup for early detection and management of such events. Although we observed no significant relationship between the type of stent and type of SRE, this may be explained by the small proportion of patients (11%) with plastic stents. Finally, there were no differences between the type of SRE developed (obstruction, infection or both) and its consequences; be it mortality, chemotherapy delay or discontinuation rate. Therefore all SREs should be considered as a medical emergency and early management is essential, due to the potentially life threatening consequences. Stentrelated events occurred early with a median timetoSRE of only 4.4 mo. Moreover, the risk increases with time rising 3fold between month 3 and month 6 and up to 80% in patients alive at 24 mo. This highlights the importance of clinician (including primary and secondary care) and patient (and their cares) awareness of early detection and treatment of a SRE. Although some guidelines suggest replacement of plastic stents every six months [18] there are no such recommendations for metallic stents. The only factor associated with a higher rate of SRE was the number of biliary stents or procedures at baseline (1 vs ≥ 2); none of the other baseline characteristics had this impact, including disease stage or site of primary tumour, highlighting the challenge that clinicians face in identifying patients at increased risk of a SRE. In addition to the number of stents at baseline, the presence of severe comorbidity was associated with earlier development of a SRE (i.e., earlier timetoSRE). The fact that stage had no impact on timetoSRE is likely to reflect the fact that stent occlusion arises from the primary (stented) disease rather than metastases, in the vast majority of patients.
The development of a SRE may be expected to be more frequent in patients receiving chemotherapy due to its known myelosuppressive effect [13] and parti cularly in patients receiving highly myelosuppressive treatment, such as FOLFIRINOX [5] . This was not con firmed in this study although this may again be due to the small number of patients receiving this regimen, and the fact that prophylactic granulocytecolony stimulating factor (GCSF) was routinely prescribed for these patients to reduce duration of neutropenia. The median timetoSRE in our study was similar to previously published data in a nonchemotherapy population [13] , suggesting that chemotherapy may not have as much as an impact on SREs as might be expected. Neither did we observe a higher rate of SREs if chemotherapy was delayed at baseline (due to potentially greater risk of tumour ingrowth). The development of a SRE did not impact on PFS; however there was a nonsignificant trend towards longer OS in the SRE group, compared with the noSRE group. This cannot be interpreted as a causality effect (patients with SRE live longer) but rather a "timeat risk" effect (patients who live longer have more time to develop a SRE). This was the main reason for including death as a "competing event" in the statistical analysis for timetoSRE. In fact, the development of a SRE did not impact on survival in the multivariable analysis for OS, confirming this approach. Importance of "time-atrisk" in the development of a SRE is also supported by the following: a higher number of patients still receiving chemotherapy at the data cutoff point in the noSRE group (8 patients vs 1 patient in the SRE group); and longer (though statistically non-significant) follow-up in the SRE group.
Our study population is representative of the population of interest when comparing characteristics such as rate of locally advanced patients; higher rate of biliary obstruction in patients with locally advanced disease [18] ; predominance of pancreatic cancer compared to biliary malignancies [19] ; median PFS and median OS (in keeping with a nontrial population). Moreover, the fact that tumour stage was identified as a prognostic factor in the multivariable analysis for OS was reassuring. The majority of patients with metallic stents at baseline is in keeping with international standards for palliative patients who are expected to be treated with chemotherapy (i.e., have an estimated survival of > 3 mo) in whom a plastic stent should not be considered as a standard [20] . The small number of patients with ECOG ≥ 2 is the likely reason why ECOG PS did not impact on OS as chemotherapy is usually considered only for patients of good performance status (PS 01 and selected PS 2 patients).
There are limitations associated with our retro spective series; although all consecutive patients with a diagnosis of advanced pancreatobiliary malig nancy were included, the patients were already pre selected by fitness and comorbidities for referral for consideration for chemotherapy. Moreover, retrospective collection of data may be subject to reporting bias. In addition, patients with different primary tumour sites were included who were in receipt of differing chemotherapeutic agents; however completeness of data and inclusion of patients from a recent era makes our findings credible. Our series did not include any nonstented patients and therefore comparisons of SRE rate between stented and notstented populations, which could be useful for assessing whether the combination of chemotherapy and biliary stent increased the risk of SRE, are not possible. Finally, most of our patients had a metal stent in situ; making our data not representative of population with plastic biliary stents.
To date, there is no evidence supporting the use of prophylactic therapy, such as antibiotics or urso deoxycholic acid, aimed at reducing or delaying SREs in these patients; thus clinicians currently treat rather than prevent SREs [33] . One purpose of our study was to generate data to inform the design of future clinical trials exploring the role of prophylaxis for the prevention or delay of SREs in this specific population. This rationale has already been investigated by some studies (summarised in Table 6 ): overall, these trials are underpowered and involved patients with both benign and malignant biliary strictures who had plastic stents in-situ. No adequatelypowered studies have been performed; neither has this question been addressed in patients with metal stents (now considered the standard of care in the palliative setting) or in a population receiving chemotherapy for advanced pancreas/biliary cancer. In 2002 the Cochrane collaboration concluded that welldesigned studies with sufficient statistical power were essential to address this issue [33] . Our results highlight the impor tance of performing adequatelypowered prospective studies looking for prevention of these events.
Stentrelated events can result in lifethreate ning complications in patients with advanced pan creatobiliary cancer who are receiving palliative chemo therapy; 43% of patients in our series developed a SRE and 63% of them had a SRErelated impact on delivery of chemotherapy or resulting in death. The risk of developing SREs increases with prolonged time on treatment and/or followup; moreover, risk is higher in patients with severe comorbidities and patients with ≥ 2 biliary stent or biliary procedures at baseline. Thus, close monitoring for early diagnosis and treatment is required. Our data will inform the design of future, prospective clinical trial(s) to evaluate how the risk of SREs and their sequelae can be reduced; as well as the clinical and socioeconomic impact of doing so.
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Background
Despite successful first biliary stenting, some patients with biliary and pancreatic malignancies will develop a stent-related event (SRE) such as recurrence of biliary obstruction (with development of new obstructive jaundice) or infection (cholangitis). Development of these events is detrimental, especially 
Investigation and result
Benign
Sciumè et al [21] , 2004 Yes Plastic 90 49/41 Ursodeoxycholic acid and levofloxacin vs Ursodeoxycholic acid alone Longer stent patency with lower cholangitis and admission rate.
(not blinded)
Katsinelos et al [22] , 2008 Yes Plastic 41 21/20 Ursodeoxycholic acid vs Placebo Common bile duct stones.
No reduction in the bile duct stone size.
(blinded)
Han et al [23] , 2009 No Plastic 28 28 Ursodeoxycholic acid and terpene Gallstones in elderly patients. Size of gallstones was reduced. Lee et al [24] , 2011
No Plastic 51 51 Ursodeoxycholic acid Gallstones in elderly patients.
No benefit of adding Ursodeoxycholic acid. Nishizawa et al [25] [27] , 1994 1 Yes Plastic 20
Not specified Ursodeoxycholic acid and norfloxacin vs Observation Longer stent patency, prolonged median survival and shorter mean hospital stay.
Luman et al [28] , 1999 Overall, studies are underpowered for reaching definitive conclusions. 1 These studies were included in The Cochrane review [33] ; 2 These studies were not included in The Cochrane review [33] .
COMMENTS
